Arcus Biosciences, Inc.
RCUS · NYSE
Earnings history and estimates
Reported and estimated revenue, EPS and post-earnings movement.
| Period | Date | Revenue actual | Revenue estimate | EPS actual | EPS estimate | 1D move |
|---|---|---|---|---|---|---|
| 2026 Q2 | August 7, 2026 | — | 22.22M | — | -1.01 | — |
| 2026 Q1 | May 5, 2026 | 17.00M | 29.48M | -1.02 | -0.92 | -0.23% |
| 2025 Q4 | February 25, 2026 | 33.00M | 35.71M | -0.89 | -1.11 | -3.60% |
| 2025 Q3 | October 28, 2025 | 26.00M | 24.94M | -1.27 | -1.33 | — |
| 2025 Q2 | August 6, 2025 | 160.00M | 32.48M | -0.08 | -1.14 | -2.21% |
| 2025 Q1 | May 6, 2025 | 28.00M | 37.36M | -1.14 | -1.02 | -1.35% |
| 2024 Q4 | February 25, 2025 | 26.00M | 29.38M | -1.03 | -1.17 | -0.98% |
| 2024 Q3 | November 6, 2024 | 48.00M | 32.06M | -1.00 | -1.07 | +4.64% |
| 2024 Q2 | August 8, 2024 | 39.00M | 25.61M | -1.02 | -1.02 | +14.02% |
| 2024 Q1 | May 8, 2024 | 145.00M | 35.56M | -0.05 | -0.97 | +5.83% |
| 2023 Q4 | February 21, 2024 | 31.00M | 28.19M | -1.08 | -1.09 | +19.87% |
| 2023 Q3 | November 7, 2023 | 32.00M | 28.33M | -0.94 | -1.12 | -2.67% |
| 2023 Q2 | August 7, 2023 | 29.00M | 30.30M | -1.04 | -1.00 | -4.26% |
| 2023 Q1 | May 9, 2023 | 25.00M | 24.97M | -1.09 | -1.06 | -3.04% |
| 2022 Q4 | February 28, 2023 | 345.00K | 23.72M | -0.93 | -0.99 | -4.34% |
| 2021 Q4 | February 23, 2022 | 354.50M | 11.85M | 3.71 | -1.13 | +18.59% |